TY - JOUR
T1 - A basic research of nuclear imaging for prostate cancer with monoclonal antibody rm2
AU - Hasegawa, Yoko
AU - Oyama, Nobuyuki
AU - Nagase, Keiko
AU - Yokoyama, Osamu
AU - Fujibayashi, Yasuhisa
AU - Furukawa, Takako
AU - Arai, Yoichi
AU - Saito, Seiichi
PY - 2010/2
Y1 - 2010/2
N2 - An immunotracer, 125Habeled RM2 (125I-RM2) has been reported to be useful for nuclear imaging of prostate cancer. According to both in vitro and in vivo studies, the uptake of 125I-RM2 in the prostate cancer cells, PC-3 and LNCaP, increased 6 hours after incubation with the tracer. This tracer uptake was blocked when the tumor cells were pretreated with unlabelled RM2. In the tumor-bearing mice, the tracer uptake was higher than that of muscle tissue at 72 hours after the tracer injection. 125I-RM2 showed excellent prostate cancer cell targeting, both in vitro and in vivo. Accordingly, RM2 seems to be a candidate for use as a radioimmunotracer ligand for prostate cancer imaging.
AB - An immunotracer, 125Habeled RM2 (125I-RM2) has been reported to be useful for nuclear imaging of prostate cancer. According to both in vitro and in vivo studies, the uptake of 125I-RM2 in the prostate cancer cells, PC-3 and LNCaP, increased 6 hours after incubation with the tracer. This tracer uptake was blocked when the tumor cells were pretreated with unlabelled RM2. In the tumor-bearing mice, the tracer uptake was higher than that of muscle tissue at 72 hours after the tracer injection. 125I-RM2 showed excellent prostate cancer cell targeting, both in vitro and in vivo. Accordingly, RM2 seems to be a candidate for use as a radioimmunotracer ligand for prostate cancer imaging.
KW - Immunotracer
KW - Prostate cancer
KW - RM2
UR - http://www.scopus.com/inward/record.url?scp=77749277463&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77749277463&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:77749277463
VL - 72
SP - 55
EP - 56
JO - Nishinihon Journal of Urology
JF - Nishinihon Journal of Urology
SN - 0029-0726
IS - 2
ER -
